首页|The emerging role of tranexamic acid and its principal target,plasminogen,in skeletal health
The emerging role of tranexamic acid and its principal target,plasminogen,in skeletal health
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
The worldwide burden of skeletal diseases such as osteoporosis,degenerative joint disease and impaired fracture healing is steadily increasing.Tranexamic acid(TXA),a plasminogen inhibitor and anti-fibrinolytic agent,is used to reduce bleeding with high effectiveness and safety in major surgical procedures.With its widespread clinical application,the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use.Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery.Also,several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing.Although a direct effect of TXA on the differentiation and function of bone cells in vitro was shown,few mechanisms of action have been reported.Here,we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and-independent mechanisms related to bone metabolism and the immune response.We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.
NETL
NSTL
万方数据
